Anti cdk8

Antibodies used were as follows: anti-Paxillin and anti-GM130 antibodies (BD Transduction Laboratories, New Jersey, USA), anti-Akap8 and anti-Nup153 (Abcam, Cambridge, UK), anti-FAK, anti-PDI, anti-p-Atf2 T71, anti-Atf2, anti-Brg1, anti-Rpb1, anti-Cdk8, anti-Cdk9, anti-Histone H4, anti-H3K4me2, anti-H3K4me3, anti-H3K27Ac, anti-Histone H3, anti-Lamin A/C and anti-GAPDH (Cell Signaling Technologies, Danvers, MA, USA), as well as anti-Ambra1 antibody (Millipore, Billerica, MA, USA). Anti-rabbit or mouse peroxidaseconjugated secondary antibodies were purchased from Cell Signaling Technologies. Cell culture FAK-deficient Squamous Cell Carcinoma (SCC) cell lines were generated as described previously (18) . SCCs were maintained in Glasgow MEM containing 10% FCS, 2 mM L-glutamine, nonessential amino acids, sodium pyruvate and MEM vitamins at 37°C, 5% CO 2 . SCC FAK-WT cells were maintained in 1 mg/ml hygromycin B. siRNA FAK-WT or FAK -/-SCC cells were transiently transfected using HiPerFect (Qiagen, Manchester, UK), according to manufacturer's protocol with a final concentration of 80 or 100 nM siRNA respectively (Supplementary Material and Methods, Table 1). Cells were analyzed at 48 h post transfection.